Department of Biological, Chemical and Pharmaceutical Science and Technologies.
Division of Cardiology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), University Hospital Paolo Giaccone, University of Palermo, Italy.
Coron Artery Dis. 2021 Jun 1;32(4):340-344. doi: 10.1097/MCA.0000000000000976.
Statin therapy has been the cornerstone for the reduction of cholesterol and circulating low-density lipoprotein (LDL) in patients with cardiovascular diseases. However, statin monotherapy has disadvantages attributable to myopathies and to the insufficient cholesterol reduction observed in some patients. There is a need for new well-tolerated therapies for lowering LDL. This review will focus on bempedoic acid in combination with traditional statin therapy or other lipid-lowering agents and its emerging role in LDL-C lowering. Bempedoic acid is also a viable alternative for reducing LDL cholesterol in the treatment of some patients suffering from heterozygous familial hypercholesterolemia.
他汀类药物治疗一直是降低心血管疾病患者胆固醇和循环低密度脂蛋白（LDL）的基石。然而，他汀类单药治疗有其缺点，如肌病和一些患者观察到的胆固醇降低不足。因此，需要新的耐受性好的降低 LDL 的治疗方法。本综述将重点介绍贝匹地酸联合传统他汀类药物或其他降脂药物治疗及其在 LDL-C 降低中的新作用。贝匹地酸也是治疗某些杂合子家族性高胆固醇血症患者降低 LDL 胆固醇的一种可行选择。
